Literature DB >> 8331734

Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

U von Schwedler1, J Song, C Aiken, D Trono.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) vif gene encodes a 23-kDa protein of unknown function, also produced by most other known lentiviruses. Vif was found to be essential for the spread of HIV-1 in peripheral blood lymphocytes and in primary macrophages, as well as in some but not all established T-cell lines. Vif was required at the stage of viral particle formation, for cell-to-cell as well as for cell-free transmission of HIV-1. Accordingly, vif-defective viruses could be complemented by the expression of vif in the producer but not in the target cell. vif-defective virions contained wild-type amounts of Gag and Env proteins, reverse transcriptase, integrase, genomic RNA, and partial reverse transcripts. Most importantly, they could enter cells normally, and the vif defect could not be rescued through the use of HIV(MLV [murine leukemia virus]) pseudotypes. Instead, vif-mutant viruses were severely impaired in their ability to complete the synthesis of proviral DNA, once internalized in the target cell. These results suggest that Vif plays a role which is novel for a retroviral protein, in allowing the processing and/or the transport of the internalized HIV core.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8331734      PMCID: PMC237882     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Human immunodeficiency virus as a prototypic complex retrovirus.

Authors:  B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

2.  HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain.

Authors:  W A O'Brien; Y Koyanagi; A Namazie; J Q Zhao; A Diagne; K Idler; J A Zack; I S Chen
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

3.  Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.

Authors:  J V Garcia; A D Miller
Journal:  Nature       Date:  1991-04-11       Impact factor: 49.962

4.  Nucleotide sequence and transcriptional analysis of molecular clones of CAEV which generate infectious virus.

Authors:  M Saltarelli; G Querat; D A Konings; R Vigne; J E Clements
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

5.  Interaction of a noncytopathic human immunodeficiency virus type 1 (HIV-1) with target cells: efficient virus entry followed by delayed expression of its RNA and protein.

Authors:  X Y Ma; K Sakai; F Sinangil; E Golub; D J Volsky
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

6.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

7.  Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products.

Authors:  E D Garrett; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein.

Authors:  B Guy; M Geist; K Dott; D Spehner; M P Kieny; J P Lecocq
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing.

Authors:  S Schwartz; B K Felber; G N Pavlakis
Journal:  Virology       Date:  1991-08       Impact factor: 3.616

10.  A human cell factor is essential for HIV-1 Rev action.

Authors:  D Trono; D Baltimore
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

View more
  192 in total

1.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

4.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

6.  Functional surfaces of the human immunodeficiency virus type 1 capsid protein.

Authors:  Uta K von Schwedler; Kirsten M Stray; Jennifer E Garrus; Wesley I Sundquist
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

8.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.

Authors:  Louis Alexander; Mary Janette Aquino-DeJesus; Michael Chan; Warren A Andiman
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Replication of chimeric human immunodeficiency virus type 1 (HIV-1) containing HIV-2 integrase (IN): naturally selected mutations in IN augment DNA synthesis.

Authors:  Marcus Padow; Lilin Lai; Champion Deivanayagam; Lawrence J DeLucas; Robert B Weiss; Diane M Dunn; Xiaoyun Wu; John C Kappes
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.

Authors:  J Goncalves; B Shi; X Yang; D Gabuzda
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.